Ohcanbohtosat - David Devos
- Čájehuvvo 1 - 20 / 54
- Sirdás čuovvovaš siidui
-
1
-
2
-
3
Seven Solutions for Neuroprotection in Parkinson's Disease Dahkki David Devos, Étienne C. Hirsch, Richard Wyse
Almmustuhtton 2020Revisão -
4
Regional siderosis: a new challenge for iron chelation therapy Dahkki Z. Ioav Cabantchik, Arnold Münnich, Moussa B. H. Youdim, David Devos
Almmustuhtton 2013Revisão -
5
-
6
-
7
Past and Future of Neurotrophic Growth Factors Therapies in ALS: From Single Neurotrophic Growth Factor to Stem Cells and Human Platelet Lysates Dahkki Flore Gouel, Anne‐Sophie Rolland, Jean‐Christophe Devedjian, Thierry Burnouf, David Devos
Almmustuhtton 2019Revisão -
8
-
9
-
10
-
11
Post translational changes to α-synuclein control iron and dopamine trafficking; a concept for neuron vulnerability in Parkinson’s disease Dahkki James A. Duce, Bruce X. Wong, Hannah Durham, Jean-Christophe Devedjian, David P. Smith, David Devos
Almmustuhtton 2017Revisão -
12
-
13
Ventilatory Dysfunction in Parkinson’s Disease Dahkki Guillaume Baille, Anna Maria De Jesus, T. Pérez, David Devos, Kathy Dujardin, C. Monaca Charley, Luc Defebvre, Caroline Moreau
Almmustuhtton 2016Revisão -
14
ACSL4 and the lipoxygenases 15/15B are pivotal for ferroptosis induced by iron and PUFA dyshomeostasis in dopaminergic neurons Dahkki Hind Bouchaoui, Laura Mahoney-Sánchez, Guillaume Garçon, Olivier Berdeaux, L. Alleman, David Devos, James A. Duce, Jean-Christophe Devedjian
Almmustuhtton 2022Artigo -
15
Panel of Oxidative Stress and Inflammatory Biomarkers in ALS: A Pilot Study Dahkki Hélène Blasco, Guillaume Garçon, Franck Patin, Charlotte Veyrat‐Durebex, Judith Boyer, David Devos, Patrick Vourc’h, Christian Andrés, Philippe Corcia
Almmustuhtton 2016Artigo -
16
The value of magnetic resonance imaging as a biomarker for amyotrophic lateral sclerosis: a systematic review Dahkki Guillaume Grolez, Caroline Moreau, Véronique Danel-Brunaud, Christine Delmaire, Renaud Lopes, Pierre Pradat, Mohamed Mounir El Mendili, Luc Defebvre, David Devos
Almmustuhtton 2016Revisão -
17
The protective effect of human platelet lysate in models of neurodegenerative disease: involvement of the Akt and MEK pathways Dahkki Flore Gouel, Bruce Do Van, Ming‐Li Chou, Aurélie Jonneaux, Caroline Moreau, Régis Bordet, Thierry Burnouf, Jean‐Christophe Devedjian, David Devos
Almmustuhtton 2016Carta -
18
-
19
Exhaustive, ONE-YEAR FOLLOW-UP OF SUBTHALAMIC NUCLEUS DEEP BRAIN STIMULATION IN A LARGE, SINGLE-CENTER COHORT OF PARKINSONIAN PATIENTS Dahkki Mélissa Tir, David Devos, S. Blond, Gustavo Touzet, Nicolas Reyns, Alain Duhamel, Olivier Cottencin, Kathy Dujardin, F. Cassim, A. Destée, Luc Defebvre, Pierre Krystkowiak
Almmustuhtton 2007Artigo -
20
Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson’s disease Dahkki Per Odin, К. Ray Chaudhuri, Jens Volkmann, Angelo Antonini, Alexander Storch, Espen Dietrichs, Zvezdan Pirtošek, Tove Henriksen, Malcolm Horne, David Devos, Filip Bergquist
Almmustuhtton 2018Revisão
Ohcanreaiddut:
Laktáseaddji fáttát
Medicine
Disease
Internal medicine
Parkinson's disease
Pathology
Biology
Neuroscience
Psychology
Amyotrophic lateral sclerosis
Biochemistry
Psychiatry
Physical medicine and rehabilitation
Dopamine
Physical therapy
Chemistry
Dopaminergic
Pharmacology
Bioinformatics
Cell biology
Neuroprotection
Radiology
Clinical trial
Deferiprone
Developmental psychology
Magnetic resonance imaging
Neurodegeneration
Oxidative stress
Rating scale
Alternative medicine
Ataxia